Impact of the Elevation Training Mask in CrossFit® Post-SARS-CoV-2 Infection.
Launched by UNIVERSITY OF VALLADOLID · Jan 30, 2025
Trial Information
Current as of June 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male aged 18 to 50 years.
- • Autonomy in training activities of CrossFit® programs, at least 1 month after the cessation of symptoms of SARS-CoV-2 infection -2 infection.
- • No hospitalization for COVID-19.
- • Autonomy in training activities of CrossFit® programs, at least 1 month after the cessation of symptoms of SARS-CoV-2 infection, to avoid residual effects of the disease and increase the safety of the athlete.
- • ≥20 months of experience training CrossFit®.
- • ≥2 participations in CrossFit® competitions in the last season.
- • Having completed Fran WODs ≤ 250 seconds before suffering from COVID-19. - Passing a complete pre-study medical examination to rule out pre-existing diseases or injuries, insisting particularly on the cardio-pulmonary examination.-- No consumption of illegal drugs according to the World Anti-Doping Agency (WADA) (stimulants, blood derivatives, anabolic) or take drugs (e.g. tramadol) or other ergogenic products.
- • Be informed about all possible risks or discomforts and benefits associated with the study and sign the informed consent form;.
- • Health sports insurance coverage.
- Exclusion Criteria:
- • Included any renal dysfunction, recent febrile illness, lower limb trauma or any history of muscle injury.
- • SARS-CoV-2 reinfection during the study.
- • Recent exposure to an altitude stimulus or hypoxia, except for the altitude of their usual residence (1063 m in Soria and 798 m in Salamanca).
- • Participants were also prevented to perform any intense physical activity outside the designed training protocol throughout the study and encouraged to follow the dietary instructions provided.
About University Of Valladolid
The University of Valladolid, a prestigious academic institution in Spain, is dedicated to advancing medical research and improving healthcare outcomes through rigorous clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive network of researchers, healthcare professionals, and state-of-the-art facilities to conduct innovative studies across various medical fields. Committed to ethical standards and patient safety, the University of Valladolid aims to contribute valuable insights to the scientific community and enhance clinical practices through evidence-based findings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Soria, , Spain
Patients applied
Trial Officials
Diego Fernández Lázaro, Vice Dean and Professor
Principal Investigator
Faculty of Health Sciences, University of Valladolid, Soria Campus (Spain)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported